Presentation is loading. Please wait.

Presentation is loading. Please wait.

Embolic Protection Devices in Transcatheter Aortic Valve Replacement: Are We Barking Up the Wrong Vascular Tree? Circulation: cardiovascular intervention.

Published byLogan Tate Modified over 6 years ago

Similar presentations

Presentation on theme: "Embolic Protection Devices in Transcatheter Aortic Valve Replacement: Are We Barking Up the Wrong Vascular Tree? Circulation: cardiovascular intervention."— Presentation transcript:

1 Embolic Protection Devices in Transcatheter Aortic Valve Replacement: Are We Barking Up the Wrong Vascular Tree? Circulation: cardiovascular intervention 2016 Arie Steinvil, Richard T. Benson, Ron Waksman

2 PPT overview Stroke in TAVR TAVR Embolic protection devices Pitfalls of current research The purpose of this manuscript was to provide an overview of the updated ongoing clinical research on embolic protection devices and present its major caveats.

3 Stroke in TAVR Mechanism of embolic stroke during TAVR
Balloon dilatation in a severely calcified valve Passage of devices at aortic arch Catheter debri Carotid disease Thrombi JACC Cardiovasc Interv. 2015;8:

4 Stroke in TAVR How is stroke defined in TAVR trials? How common is clinical stroke in TAVR? How common is silent CNS infarction?

5 Stroke in TAVR New definition of stroke
Stroke. 2013;44: AHA/ASA : An Updated Definition of Stroke for the 21st Century.

6 Stroke in TAVR Silent CNS infarction
Silent infarcts are well recognized to be associated with several adverse neurological and cognitive consequences: Impaired mobility, Physical decline, Depression, Cognitive dysfunction, Dementia Parkinson’s disease, Alzheimer disease . Stroke. 2013;44: AHA/ASA An Updated Definition of Stroke for the 21st Century.

7 Stroke in TAVR Silent CNS infarction Figure of brain and rates Fingerprints statement Stroke. 2013;44: An Updated Definition of Stroke for the 21st Century.

8 Stroke in TAVR Silent CNS infarction in TAVR
This is nice review we have found showing that since the more frequent use of DW MRI higher rates of post procedural silent infarctions have been found.

9 Stroke in TAVR % % Partner cohort B Partner cohort A
30 d Stroke or TIA

10 Updated 30-d all neuro events rates
Stroke in TAVR Updated 30-d all neuro events rates

11 % Stroke in TAVR New Silent CNS infarction following TAVR
Clinical stroke: / / /60

12 Multiple, small, widespread, clinically silent
Stroke in TAVR Multiple, small, widespread, clinically silent

13 PPT overview Stroke in TAVR TAVR Embolic protection devices Pitfalls of current research The purpose of this manuscript was to provide an overview of the updated ongoing clinical research on embolic protection devices and present its major caveats.

14 Trans catheter EPD Deflector Filter Device Embrella TriGuard Sentinel
Manufacturer Design Access Delivery Deployment Embrella Edwards Lifesciences, Irvine, CA, USA Deflector Radial/ brachial 6 Fr Aortic arch TriGuard Keystone Heart Ltd, Caesarea, Israel Femoral 9 Fr Sentinel Claret Medical Inc., Santa Rosa, CA, USA Filter Two filters to brachiocephalic trunk and left common carotid

15 Embolic protection devices
Embrela However since than newer data has shown much lower rates of stroke in TAVR Show a slide of the newer articles and Corvalve Mechanism of stroke withtavr – show slide

16 Embolic protection devices
Embrela PROTAVI-C pilot study J Am Coll Cardiol Intv 2014;7:1146–55.

17 Embolic protection devices
Embrela PROTAVI-C pilot study J Am Coll Cardiol Intv 2014;7:1146–55.

18 Embolic protection devices
Triguard

19 Embolic protection devices
Triguard

20 Embolic protection devices
Triguard No baseline MRI because because the researchers assumed a high baseline rate of silent ischemia …. European Heart Journal 2015

21 Embolic protection devices
Triguard No baseline MRI because because the researchers assumed a high baseline rate of silent ischemia ….

22 Embolic protection devices
Triguard No baseline MRI because because the researchers assumed a high baseline rate of silent ischemia …. European Heart Journal 2015

23 Embolic protection devices
Triguard Safety No baseline MRI because because the researchers assumed a high baseline rate of silent ischemia …. European Heart Journal 2015

24 Embolic protection devices
Triguard efficacy Reduction in lesion number Reduction in lesion volume No statistical significance* TriGuard use was associated with greater freedom from new ischaemic brain lesions (26.9 vs. 11.5%), European Heart Journal 2015

25 Embolic protection devices
Triguard cognitive Lower NIHSS score on discharge Improved Montreal Cognitive Assessment (MoCA) scores. Better performance on a delayed memory task at discharge. NIH stroke scale Montreal Cognitive Assessment score fewer new neurologic deficits detected by the National Institutes of Health Stroke Scale (3.1 vs. 15.4%), improved Montreal Cognitive Assessment (MoCA) scores, better performance on a delayed memory task (P¼0.028) at discharge, and a .2-fold increase in recovery of normal cognitive function (MoCAscore .26) at 30 days. European Heart Journal 2015

26 Embolic protection devices
Triguard No baseline MRI because because the researchers assumed a high baseline rate of silent ischemia ….

27 Embolic protection devices
Claret device/Sentienl Clean TAVI Sentinel

28 Embolic protection devices
Claret device/Sentinel Clean TAVI trial

29 Embolic protection devices
Claret device/Sentinel Clean TAVI trial

30 Embolic protection devices
Claret device/Sentinel Clean TAVI trial

31 Embolic protection devices
Claret device/Sentinel Clean TAVI trial

32 Embolic protection devices
Claret device/Sentinel Sentinel trial

33 Embolic protection devices
Claret device/Sentinel Sentinel trial

34 Embolic protection devices
Claret device/Sentinel Sentinel trial

35 PPT overview Stroke in TAVR TAVR Embolic protection devices Pitfalls of current research The purpose of this manuscript was to provide an overview of the updated ongoing clinical research on embolic protection devices and present its major caveats.

36 Pitfalls of current research
Brain infarct, stroke, and silent stroke Use of DW MRI Neuro-cognitive testing Cardiac surgery perspective However since than newer data has shown much lower rates of stroke in TAVR Show a slide of the newer articles and Corvalve Mechanism of stroke withtavr – show slide

37 Pitfalls of current research
Brain infarct, stroke, and silent stroke Clinical manifestations of embolism depend on: Number Volume Type Location Cerebral tissue condition Temporal profile of the particle shower CNS infarct ≠ Clinical stroke CNS infarct ≠ Clinical stroke Just the presence of particulate debris in brain matter may not correlate with the extent of brain injury or clinical function as a slower rate of particle release may have less potential for ischemic injury than the same number of particles delivered in a sudden shower, and given an identical embolic insult, cerebral tissue with reduced perfusion pressure has a greater risk of permanent ischemic injury than cerebral tissue with normal perfusion pressure Derdeyn CP. Diffusion-weighted imaging as a surrogate marker for stroke as a complication of cerebrovascular procedures and devices. AJNR Am J Neuroradiol. 2001;22:

38 Pitfalls of current research
Brain infarct, stroke, and silent stroke EPD trial define surrogate markers of the disease as the primary outcome Not recommended by the AHA/ASA guidelines

39 Pitfalls of current research
Brain infarct, stroke, and silent stroke EPD trial do not use updated stroke definitons which include silent CNS ischemia

40 Pitfalls of current research
Use of DW MRI Lack of long term DW MRI follow up The number of CNS lesions: Increase following TAVR Reduce with time 45 TAVI patients at baseline 17 at 6 months J Cardiovasc Magn Reson. 2013; 15(Suppl 1): O59.

41 Pitfalls of current research
Use of DW MRI Switch from 1.5T to 3T Inability to compare to historic cohorts Enhanced sensitivity might cause over estimation of lesions otherwise ignored in real world setting No standardization

42 Pitfalls of current research
Neuro-cognitive testing ‘Neurocognitive assessment battery’ Interobserver variability No standardization No long term follow up in trials Current TAVR patients have other reasons for cognitive decline

43 Pitfalls of current research
Neuro-cognitive testing ‘ Cognitive function in 111 TAVR D M Y Y Overall Cognition intact for > 90% for 2y after TAVR Circ interventions Cognitive Trajectory After Transcatheter Aortic Valve Implantation

44 Pitfalls of current research
Cardiac surgery perspective

45 Pitfalls of current research
Cardiac surgery perspective This road has been taken… No EPD used EPD trials EPD devices New post op CNS lesions on MRI

46 Pitfalls of current research
Cardiac surgery perspective Similar to TAVR The number of CNS lesions: Increase following SAVR Reduce with time 21 SAVR patients at baseline 18 at 6 months J Cardiovasc Magn Reson. 2013; 15(Suppl 1): O59.

47 Pitfalls of current research
Cardiac surgery perspective Similar to TAVR MRI Lesions were multiple, small, widespread Weakness in the reproducibility and objectivity of neurocognitive testing Various protection devices tested without benefit

48 Summary Silent stroke in TAVR is common Stroke is not
. The clinical significance of silent stroke In TAVR is unknown

49 Summary EPD may reduce silent CNS infarcts EPD may reduce cognitive decline . EPD Trials investigate surrogate markers, not yet proven to cause harm

50 Thank you What is the true significance of new post TAVR CNS lesions?
No EPD used EPD trials EPD devices New post op CNS lesions on MRI

Download ppt "Embolic Protection Devices in Transcatheter Aortic Valve Replacement: Are We Barking Up the Wrong Vascular Tree? Circulation: cardiovascular intervention."

Similar presentations

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..
ACST-2 Ophthalmic sub-study Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Chairman, Dept. of Vascular Surgery,

ACST-2 Ophthalmic sub-study Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Chairman, Dept. of Vascular Surgery,
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.

Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Stroke & its consequences Patient WW Medical history: – History of high blood pressure (hypertension) – Massive Stroke in Right Hemisphere Behavioral changes:

Stroke & its consequences Patient WW Medical history: – History of high blood pressure (hypertension) – Massive Stroke in Right Hemisphere Behavioral changes:
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.

A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Meredith Cook – PharmD Candidate Mercer University COPHS August, 2012 Cognitive Trajectories after Postoperative Delirium.

Meredith Cook – PharmD Candidate Mercer University COPHS August, 2012 Cognitive Trajectories after Postoperative Delirium.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.

The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.

Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.
UC201300969c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.

UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc. 2011.

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.

: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.

Similar presentations

Ads by Google